Sunshine Biopharma Inc. — Form 10-Q Summary
Reporting period: Quarter ended September 30, 2011; financial statements are unaudited. Sunshine Biopharma is a development-stage pharmaceutical company focused on cancer drug research and development.
Financial results and position
| Metric | Period / date | Reported amount |
|---|---|---|
| Revenue | Three and nine months ended September 30, 2011 | $0 |
| Net loss | Three months ended September 30, 2011 | $116,441 |
| Net loss | Nine months ended September 30, 2011 | $184,146 |
| Basic loss per share | Nine months ended September 30, 2011 | $0.01 |
| Cash and cash equivalents | September 30, 2011 | $178,473 |
| Current assets, including prepaid expenses | September 30, 2011 | $224,218 |
| Current liabilities | September 30, 2011 | $4,545 |
| Total assets / shareholders’ equity | September 30, 2011 | $224,218 / $219,673 on balance sheet |
| Net cash used in operating activities | Nine months ended September 30, 2011 | $179,518 |
| Net cash provided by financing activities | Nine months ended September 30, 2011 | $195,600 |
| Debt | September 30, 2011 | No debt is reported on the balance sheet |
No gross or operating margins are meaningful because the company reported no revenue. Cash increased by $16,082 during the nine-month period.
Changes versus comparable periods
- For the third quarter, net loss narrowed to $116,441 from $160,435 in the 2010 quarter. General and administrative expense fell by $43,994; the 2011 quarter included $100,000 of licensing fees, while the 2010 quarter included a $50,000 intangible-asset write-down.
- For the nine months, net loss declined to $184,146 from $1,133,129 in the comparable 2010 period. The earlier period included $945,974 of intangible-asset write-downs and $155,150 of merger costs; neither item was reported in 2011. The filing also reports higher 2011 costs in several operating categories, including research and development.
- Nine-month operating cash use decreased to $179,518 from $469,155. Financing cash inflow was $195,600, compared with $649,000 in 2010.
Business outlook, risks and other notable matters
- The lead candidate, Adva-27a, is a preclinical cancer compound licensed exclusively from Advanomics. The company reported laboratory findings it describes as promising; these are preclinical claims, not evidence of clinical efficacy.
- The company planned Phase I trials for multidrug-resistant breast cancer at Montreal’s Jewish General Hospital, with a stated target to begin in late 2013 and complete trials by late 2014. These plans depend on obtaining financing and successful development; the filing gives no assurance they will occur.
- Management estimated approximately $7.5 million of debt and/or equity capital would be needed to implement its business plan. No definitive financing commitment was in place as of the report date. Management warned that insufficient funding could materially adversely affect operations and financial condition, and said it lacked funds for anticipated increases in costs, including clinical trials.
- A research agreement with Binghamton University is funding-dependent and may terminate if adequate funding is not secured. Management said funding had been provided by the company to date but full project funding was not secured.
- The company reported no legal proceedings, defaults on senior securities, or changes in internal control over financial reporting. Management concluded disclosure controls were effective as of September 30, 2011.
- The company issued 326,000 common shares during the quarter. The filing reports $195,600 of proceeds in its financial statements, but gives conflicting per-share prices in different sections.
Important facts for investors to verify
- Reconcile the quarterly share issuance price: Part II states $0.60 per share, while the shareholders’ equity statement appears to state $1.67 per share; reported proceeds of $195,600 correspond to $0.60 for 326,000 shares.
- Reconcile the $1 difference between shareholders’ equity of $219,673 on the balance sheet and $219,674 in the statement of shareholders’ equity.
- Confirm the status and availability of financing, including the estimated $7.5 million capital requirement and funding for the research and clinical-trial plans.
- Assess the development timeline and clinical plans in light of the candidate’s preclinical stage and the absence of revenue.
- Review the complete audited 2010 Form 10-K and underlying license and research agreements; this 10-Q refers readers to the prior filing for complete footnotes.